Anticoagulation in the treatment of established venous thromboembolism in patients with cancer

Journal of Clinical Oncology

Volumn 27, Issue 29, 2009, Pages 4895-4901

  Lee, Agnes Y Y ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ANTINEOPLASTIC AGENT; ANTIVITAMIN K; APIXABAN; DABIGATRAN ETEXILATE; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; IDRAPARINUX; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN; TINZAPARIN; WARFARIN; ANTICOAGULANT AGENT;

ANTICOAGULANT THERAPY; BLEEDING; BLEEDING DISORDER; CANCER PATIENT; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MORBIDITY; MORTALITY; PATIENT CARE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; VENA CAVA FILTER; VENOUS THROMBOEMBOLISM; DOPPLER ECHOGRAPHY; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; FOLLOW UP; HOSPITALIZATION; MALE; METHODOLOGY; NEOPLASM; PATHOLOGY; PHLEBOGRAPHY; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SURVIVAL;

ANTICOAGULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EVIDENCE-BASED MEDICINE; FEMALE; FOLLOW-UP STUDIES; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; NEOPLASMS; PHLEBOGRAPHY; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME; ULTRASONOGRAPHY, DOPPLER, DUPLEX; VENOUS THROMBOEMBOLISM;

EID: 70350702989     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.22.3958     Document Type: Review

References (42)

1. Khorana AA, Francis CW, Culakova E, et al: Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 24:484-490, 2006
2. Stein PD, Beemath A, Meyers FA, et al: Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med 119:60-68, 2006
3. Kearon C, Kahn SR, Agnelli G, et al: Anti-thrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133:454S-545S, 2008 (suppl 6)
4. Baglin TP, Keeling DM, Watson HG: Guidelines on oral anticoagulation (warfarin): Third edition - 2005 update. Br J Haematol 132:277-285, 2006
5. Wagman LD, Baird MF, Bennett CL, et al: Venous thromboembolic disease: Clinical practice guidelines in oncology. J Natl Compr Canc Netw 4:838-869, 2006
6. Lyman GH, Khorana AA, Falanga A, et al: American Society of Clinical Oncology guideline: Recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25:5490-5505, 2007
7. Lee AY, Levine MN, Baker RI, et al: Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349:146-153, 2003
8. Meyer G, Marjanovic Z, Valcke J, et al: Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: A randomized controlled study. Arch Intern Med 162: 1729-1735, 2002
9. Deitcher SR, Kessler CM, Merli G, et al: Secondary prevention of venous thromboembolic events in patients with active cancer: Enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost 12:389-396, 2006
10. Hull RD, Pineo GF, Brant RF, et al: Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 119:1062-1072, 2006
11. Monreal M, Zacharski L, Jimenez JA, et al: Fixed-dose low-molecular-weight heparin for secondary prevention of venous thromboembolism in patients with disseminated cancer: A prospective cohort study. J Thromb Haemost 2:1311-1315, 2004
12. Prandoni P, Lensing AW, Piccioli A, et al: Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100:3484-3488, 2002
13. Warkentin TE, Greinacher A, Koster A, et al: Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133:340S-380S, 2008 (suppl 6)
14. Hirsh J, Bauer KA, Donati MB, et al: Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133:141S-159S, 2008 (suppl 6)
15. Leizorovicz A: Tinzaparin compared to unfractionated heparin for initial treatment of deep vein thrombosis in very elderly patients with renal insufficiency: The IRIS trial. Blood 104:434, 2008 (abstr)
16. United States Food and Drug Administration Center for Drug Evaluation and Research: Communication about an Ongoing Safety Review of Innohep (tinzaparin sodium injection). http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformation forPatientsandProviders / DrugSafetyInformationfor HeathcareProfessionals/ucm136254.htm
17. Hutten BA, Prins MH, Gent M, et al: Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: A retrospective analysis. J Clin Oncol 18:3078-3083, 2000
18. van Dongen CJ, van den Belt AG, Prins MH, et al: Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev 4:CD001100, 2004
19. Avritscher EB, Cantor SB, Shih YC, et al: Cost-minimization analysis of low-molecular-weight heparin (dalteparin) compared to unfractionated heparin for inpatient treatment of cancer patients with deep venous thrombosis. Support Care Cancer 12: 531-536, 2004
20. Kearon C, Ginsberg JS, Julian JA, et al: Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA 296:935-942, 2006
21. Breddin HK, Hach-Wunderle V, Nakov R, et al: Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis. N Engl J Med 344:626-631, 2001
22. Kakkar AK, Breddin HK, Kakkar VV, et al: Treatment of deep vein thrombosis in cancer: A comparison of unfractionated and low molecular weight heparin. Blood 96:449a, 2000 (abstr 1934)
23. Lee AY: Management of thrombosis in cancer: Primary prevention and secondary prophylaxis. Br J Haematol 128:291-302, 2005
24. Levine M, Gent M, Hirsh J, et al: A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 334:677-681, 1996
25. Koopman MM, Prandoni P, Piovella F, et al: Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home: The Tasman Study Group. N Engl J Med 334:682-687, 1996
26. Columbus Investigators: Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 337:657-662, 1997
27. Merli G, Spiro TE, Olsson CG, et al: Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med 134:191-202, 2001
28. Büller HR, Davidson BL, Decousus H, et al: Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 349:1695-1702, 2003
29. Büller HR, Davidson BL, Decousus H, et al: Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: A randomized trial. Ann Intern Med 140:867-873, 2004
30. 29a. van Doormaal FF, Raskob GE, Davidson BL, et al: Treatment of venous thromboembolism in patients with cancer: Subgroup analysis of the Matisse clinical trials. Thromb Haemost 101:762-769, 2009
31. Buller HR, Cohen AT, Davidson B, et al: Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med 357:1094-1104, 2007
32. Buller HR, Cohen AT, Davidson B, et al: Extended prophylaxis of venous thromboembolism with idraparinux. N Engl J Med 357:1105-1112, 2007
33. Weitz JI, Hirsh J, Samama MM: New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133:234S-256S, 2008 (suppl 6)
34. 32a. Liebman H, Levine MN, Deitchman D, et al: Apixaban in patients with metastatic cancer: A randomized phase II feasibility study. Presented at the XXII Congress of the International Society on Thrombosis and Haemostasis, July 11-16, 2009, Boston, MA
35. Elting LS, Escalante CP, Cooksley C, et al: Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med 164: 1653-1661, 2004
36. Billett HH, Jacobs LG, Madsen EM, et al: Efficacy of inferior vena cava filters in anticoagulated patients. J Thromb Haemost 5:1848-1853, 2007
37. Decousus H, Leizorovicz A, Parent F, et al: A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis: Prevention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med 338:409-415, 1998
38. Prevention du Risque d'Embolie Pulmonaire par Interruption Cave Investigators: Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: The PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study. Circulation 112:416-422, 2005
39. Luk C, Wells PS, Anderson D, et al: Extended outpatient therapy with low molecular weight heparin for the treatment of recurrent venous thromboembolism despite warfarin therapy. Am J Med 111: 270-273, 2001
40. Carrier M, Le Gal G, Cho R, et al: Dose escalation of low molecular weight heparin to mange recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients. J Thromb Haemost 7:760-765, 2009
41. Getzen TM, Rectenwald JE: Inferior vena cava filters in the cancer patient: Current use and indications. J Natl Compr Canc Netw 4:881-888, 2006
42. Herishanu Y, Misgav M, Kirgner I, et al: Enoxaparin can be used safely in patients with severe thrombocytopenia due to intensive chemotherapy regimens. Leuk Lymphoma 45:1407-1411, 2004